# LAURA (NCT03521154)

> A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03521154
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non Small Cell Lung Cancer (Stage III)
- Interventions: Osimertinib 80mg/40mg; Placebo Osimertinib 80mg/40mg
- Enrollment: 216
- Primary outcome: Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)

## Commentary we found

- X threads: 7

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=laura-nct03521154